메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

AXA Signs Cooperation Agreement with Hainan Boao Lecheng Administration

[ 메디채널 김갑성 기자 ] Jointly explore innovative medical insurance services to provide customers with diverse and high-quality healthcare options HONG KONG, Aug. 8, 2025 -- AXA China Region Insurance Company (Bermuda) Limited ("AXA") formally signed an official cooperation agreement with Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration ("Lecheng Administration"). The partnership aims jointly explore more innovative medical insurance models and leverage the top-tier medical resources of Hainan Boao Lecheng to provide customers with more high-qu
- 김갑성 기자
- 2025-08-08 17:48
Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests

[ 메디채널 김갑성 기자 ] Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring. HONG KONG, Aug. 8, 2025 -- Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, today announced an exclusive collaboration with Pacific Edge, the developer of the Cxbladder suite of non-invasive genomic urine tests, to bring its advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong. Under this partnership, Codex Genetics will offer access to Cxbladder's full rang
- 김갑성 기자
- 2025-08-08 17:45
WuXi XDC Included in MSCI China All Share Index

SHANGHAI, Aug. 8, 2025 -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the MSCI China All Share Index, which underscores global capital markets' recognition of the company's sustained growth value and leadership in the bioconjugate CRDMO sector. The inclusion will take place as of the close of August 26, 2025. The MSCI China All Share Index is a free-float-adjusted market-capitalization-weighted index designed
- 김갑성 기자
- 2025-08-08 17:32
소비자 5명 중 4명은 건강기능식품 섭취, 그 중 절반은 올바르게 제품을 선택했는지에 대한 의구심을 가지고 있어 - 허벌라이프 조사 결과 발표

예방 중심의 건강 트렌드 확산 속 신뢰할 수 있는 정보에 대한 수요 증가 홍콩 2025년 8월 8일 -- 건강 및 웰니스 뉴트리션 전문 글로벌 기업 허벌라이프(Herbalife)가 6일 '2025 아시아 태평양 올바른 건강기능식품 섭취 조사(2025 Asia Pacific Responsible Supplementation Survey)' 결과를 발표했다. 조사에 따르면 아시아 태평양 지역 소비자 대다수(80%)는 건강기능식품을 정기적으로 섭취하고 있지만, 올바르게 제품을 선택할 수 있다고 응답한 비율은 절반(50%)에 불과해, 많은 소비자들이 자신의 선택에 확신을 갖지 못하는 것으로 나타났다. 이번 조사는 2025년 5월, 한국을 포함한 아태지역 11개 시장(호주, 홍콩, 인도네시아, 일본, 말레이시아, 필리핀, 싱가포르, 대만, 태국, 베트남) 소비자들의 건강기능식품에 대한 이해와, 이후 선택과 섭취 등의 행동 성향을 알아보기 위해 실시됐다. 조사에서의 '올바른 건강기능식품의 선택'이란 표현은 제품 섭취 전 성분 구성, 품질, 권장 섭취량, 섭취 한도는 물론, 다른 건강기능식품이나 의약품과의 상호작용
- 김갑성 기자
- 2025-08-08 10:49
WCC Biomedical@NACDS Total Store Expo: Advancing Microneedle Drug Delivery With WINMAP™ Platform

TAIPEI, Aug. 8, 2025 -- WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launch two new products. To explore WINMAP™ technology for vaccines and pharmaceuticals, join WCC at the Total Store Expo on August 23–25 in San Diego, CA: Booth # 900 Following a successful debut at BIO Asia in Taiwan (July 23–27), WCC will offer demonstrations of its new products at TSE, allowing attendees to witness the benefits of microneedle-based
- 김갑성 기자
- 2025-08-08 09:30
CHICAGO RIVER SWIM APPROVED FOR HISTORIC RETURN THIS SEPTEMBER

[ 메디채널 김갑성 기자 ] First Organized Swim in Nearly a Century will Raise Funds for ALS Research and Youth Swimming Lessons WHAT: Open Water Swim in the Main Stem of the Chicago RiverWHEN: September 21, 2025 | 7:00AM – 10:00AMWEBSITE: ChicagoRiverSwim.org CHICAGO, Aug. 7, 2025 -- The City of Chicago has officially approved the 2025 Chicago River Swim, the first organized open water swim in the river in nearly a century. Scheduled for Sunday, September 21, the event will highlight the city's environmental progress while raising funds for ALS research at Nort
- 김갑성 기자
- 2025-08-08 05:15
LabConnect Partners with Kits4Life to Reduce Kit Waste and Advance Sustainable Clinical Trials

JOHNSON CITY, Tenn., Aug. 8, 2025 -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an initiative of the MedSurplus Alliance. This collaboration reflects our broader ESG strategy and strengthens LabConnect's role as the world's most agile and responsible central laboratory services provider. Through this partnership, LabConnect will work with sponsors and clinical sites to identify and manage eligible kits for donation, reducing landfill waste while
- 김갑성 기자
- 2025-08-08 00:40
Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion

SHANGHAI, Aug. 7, 2025 -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led by Qiming Venture Partners. Further support came from existing investor TF Capital, and seven new investors, including including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's Board of Directors. Proceeds will be used to advance the company
- 김갑성 기자
- 2025-08-07 18:00
US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second program IND has been submitted to US FDA for clinical trial targeting MYC-aberrant lymphoma. Following the initiation of the first trial using CX-5461 as a monotherapy in advanced solid tumors, the IND-submission of the second trial marks a milestone in the development of CX-5461. With
- 김갑성 기자
- 2025-08-07 14:35
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99 billion, represents one of the largest commitments to date for
- 김갑성 기자
- 2025-08-07 08:05

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 15시 40분